Jeff Ajer

Executive Vice President & Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

Jeff Ajer

Jeff Ajer

Executive Vice President & Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

Overview
RelSci Relationships

986

Number of Boards

3

Birthday

1962

Age

56

Relationships
RelSci Relationships are individuals Jeff Ajer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Nektar Therapeutics

Relationship likelihood: Strong

President & Chief Executive Officer at True North Therapeutics, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Retrophin, Inc.

Relationship likelihood: Strong

General Partner at Hatteras Venture Partners

Relationship likelihood: Strong

Former Executive Vice President & Chief Financial Officer at Owens & Minor, Inc.

Relationship likelihood: Strong

Former Chief Financial Officer & Senior Vice President at Applera Corporation

Relationship likelihood: Strong

Founder at Numenor Ventures LLC

Relationship likelihood: Strong

Co-Founder at Incyte Corp.

Relationship likelihood: Strong

Former Chief Executive Officer at Covance, Inc.

Relationship likelihood: Strong

Paths to Jeff Ajer
Potential Connections via
Relationship Science
You
Jeff Ajer
Executive Vice President & Chief Commercial Officer at BioMarin Pharmaceutical, Inc.
Education
Undergraduate Degree

University of California, Irvine is a public research university located in Irvine, California and one of the 10 general campuses in the University of California (UC) system. UCI's Orange County campus is the fifth-largest in the UC system. UC Irvine is considered a Public Ivy and became a member of the Association of American Universities in 1996, and is the youngest university to hold membership. It also administers the UC Irvine Medical Center, a large teaching hospital; the UC Irvine Health Sciences system in the City of Orange; the University of California, Irvine, Arboretum; and a portion of the University of California Natural Reserve System.

Career History
Executive Vice President & Chief Commercial Officer
2005 - Current

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Vice President-Global Transplant Operations
2003 - 2005

Genzyme Corp. develops and manufactures specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Senior Director-Sales Operations, Bids & Contracts
Prior - 2003
Boards & Committees
Member, Board of Directors
2017 - Current

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Independent Director
2017 - Current

True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA.

Member, Board of Directors
Prior
Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jeff Ajer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jeff Ajer's profile does not indicate a business or promotional relationship of any kind between RelSci and Jeff Ajer.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/jeff-ajer-3834754
  • https://relationshipscience.com/person/jeff-ajer-3834754